Bone Biologics Corp. (NASDAQ:BBLG) Short Interest Up 1,315.5% in June

Bone Biologics Corp. (NASDAQ:BBLG) was the recipient of a significant increase in short interest during the month of June. As of June 30th, there was short interest totaling 67,279 shares, an increase of 1,315.5% from the June 15th total of 4,753 shares. Currently, 4.0% of the shares of the stock are short sold. Based on an average daily volume of 201,808 shares, the days-to-cover ratio is currently 0.3 days.

Institutional Investors Weigh In On Bone Biologics

A hedge fund recently raised its stake in Bone Biologics stock. DRW Securities LLC grew its position in shares of Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 23,576 shares of the company’s stock after acquiring an additional 12,549 shares during the quarter. DRW Securities LLC owned about 1.31% of Bone Biologics worth $34,000 at the end of the most recent quarter. 34.30% of the stock is owned by hedge funds and other institutional investors.

Bone Biologics Stock Up 0.7%

Shares of BBLG traded up $0.01 on Friday, hitting $1.39. 24,135 shares of the stock traded hands, compared to its average volume of 143,856. The firm has a market capitalization of $2.50 million, a P/E ratio of -0.61 and a beta of 0.90. The stock’s 50 day moving average is $1.32 and its two-hundred day moving average is $1.37. Bone Biologics has a 1 year low of $1.05 and a 1 year high of $4.13.

Bone Biologics (NASDAQ:BBLG) last released its earnings results on Thursday, May 14th. The company reported ($0.43) EPS for the quarter, hitting the consensus estimate of ($0.43). Research analysts forecast that Bone Biologics will post -1.17 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Bone Biologics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Monday, April 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

About Bone Biologics

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.